Embecta (NASDAQ:EMBC) Releases Earnings Results, Beats Estimates By $0.20 EPS

Embecta (NASDAQ:EMBC) issued its quarterly earnings data on Thursday. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.45 by $0.20, Zacks reports. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.

Embecta Stock Performance

Embecta stock opened at $17.42 on Friday. Embecta has a fifty-two week low of $9.93 and a fifty-two week high of $21.48. The stock has a market cap of $1.01 billion, a P/E ratio of 17.42, a price-to-earnings-growth ratio of 0.95 and a beta of 1.20. The firm’s fifty day moving average price is $19.65 and its 200-day moving average price is $16.53.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Friday, February 28th. Embecta’s payout ratio is 60.00%.

Analyst Ratings Changes

EMBC has been the subject of a number of recent analyst reports. BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday, November 27th. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.